Related Experiment Video
Updated: Aug 11, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines
Abstract:
We have compared the in vitro activity of N-trifluoroacetyladriamycin-14-valerate (AD-32) and doxorubicin hydrochloride (ADR) on the clonal growth of human bladder tumor cell lines (HBTCL). In order to determine the relatively toxicity of ADR and AD-32 on hematopoietic stem cells, CFU-GM assays were set up using 10 normal human bone marrow samples. The mean lethal dose for 50% of the colonies (LD-50) for ADR was 1.6 +/- 1.4 microM and that for AD-32, 3.9 +/- 4.9 microM (P less than 0.55), suggesting that these agents have similar bone marrow toxicity. Both drugs produced enhanced inhibition of clonal growth of HBTCL with increasing C X Ts. The spectrum of activity of the two drugs was similar against a panel of seven HBTCL. The activity of ADR was inhibited at 4 degrees C while the activity of AD-32 was unaffected by temperature. ADR was more effective against HBTCL in the log growth phase than the plateau phase while the reverse was found using AD-32. Verapamil was found to enhance the activity of both ADR and AD-32 against a HBTCL (T24), found to be resistant to both agents. The lipophilic properties of AD-32, along with its enhanced activity when used over prolonged periods of time and its activity against tumor cells in the plateau phase, suggest that AD-32 could be useful in the management of patients with superficial bladder cancer.
Insights
N-trifluoroacetyladriamycin-14-valerate (AD-32) and doxorubicin hydrochloride (ADR) show similar bone marrow toxicity. AD-32 demonstrates potential for treating superficial bladder cancer due to its activity against tumor cells in plateau phase.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Doxorubicin hydrochloride (ADR) is a standard chemotherapy agent.
- N-trifluoroacetyladriamycin-14-valerate (AD-32) is a novel analog of doxorubicin.
- Understanding the comparative efficacy and toxicity of these agents is crucial for bladder cancer treatment.
Purpose of the Study:
- To compare the in vitro activity and toxicity of AD-32 and ADR against human bladder tumor cell lines (HBTCL).
- To evaluate the impact of temperature and growth phase on drug activity.
- To assess the potential of AD-32 in managing superficial bladder cancer.
Main Methods:
- In vitro assessment of clonal growth inhibition of HBTCL by AD-32 and ADR.
- Colony-forming unit-granulocyte-macrophage (CFU-GM) assays using human bone marrow samples to determine toxicity.
- Evaluation of drug activity at different temperatures (4°C vs. 37°C) and cell growth phases (log vs. plateau).
- Assessment of verapamil's effect on drug activity in resistant cell lines.
Main Results:
- AD-32 and ADR exhibited similar bone marrow toxicity, with comparable mean lethal doses (LD-50).
- Both agents inhibited HBTCL clonal growth in a dose-dependent manner.
- AD-32 retained activity at 4°C, unlike ADR, and was more effective against plateau-phase cells, whereas ADR was more effective against log-phase cells.
- Verapamil enhanced the activity of both drugs against a resistant HBTCL (T24).
Conclusions:
- AD-32 and ADR possess similar bone marrow toxicity profiles.
- AD-32's lipophilicity, sustained activity, and efficacy against plateau-phase bladder tumor cells suggest its potential utility in superficial bladder cancer treatment.
- Further investigation into AD-32's therapeutic role is warranted.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:243-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
Published on: September 13, 2018